

John P Mueller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2092418/publications.pdf>

Version: 2024-02-01

19
papers

953
citations

687363

13
h-index

794594

19
g-index

19
all docs

19
docs citations

19
times ranked

885
citing authors

#	ARTICLE	IF	CITATIONS
1	ETX2514 is a broad-spectrum \hat{I}^2 -lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including <i>Acinetobacter baumannii</i> . <i>Nature Microbiology</i> , 2017, 2, 17104.	13.3	187
2	Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea. <i>New England Journal of Medicine</i> , 2018, 379, 1835-1845.	27.0	148
3	Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. <i>Scientific Reports</i> , 2015, 5, 11827.	3.3	85
4	Characterization of the Novel DNA Gyrase Inhibitor AZD0914: Low Resistance Potential and Lack of Cross-Resistance in <i>Neisseria gonorrhoeae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1478-1486.	3.2	74
5	Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of <i>Neisseria gonorrhoeae</i> , Including Multi-Drug-Resistant Isolates. <i>ACS Infectious Diseases</i> , 2020, 6, 1332-1345.	3.8	73
6	<i>In Vitro</i> Antibacterial Activity of AZD0914, a New Spiropyrimidinetrione DNA Gyrase/Topoisomerase Inhibitor with Potent Activity against Gram-Positive, Fastidious Gram-Negative, and Atypical Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 467-474.	3.2	67
7	High <i>In Vitro</i> Activity of the Novel Spiropyrimidinetrione AZD0914, a DNA Gyrase Inhibitor, against Multidrug-Resistant <i>Neisseria gonorrhoeae</i> Isolates Suggests a New Effective Option for Oral Treatment of Gonorrhea. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5585-5588.	3.2	62
8	Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914). <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6264-6282.	6.4	60
9	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine \hat{I}^2 -Lactamases. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12511-12525.	6.4	44
10	Inhibition of <i>Neisseria gonorrhoeae</i> Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914. <i>Journal of Biological Chemistry</i> , 2015, 290, 20984-20994.	3.4	34
11	Multidrug-Resistant <i>Neisseria gonorrhoeae</i> Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914). <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 621-623.	3.2	26
12	<i>In Vitro</i> Characterization of ETX1317, a Broad-Spectrum \hat{I}^2 -Lactamase Inhibitor That Restores and Enhances \hat{I}^2 -Lactam Activity against Multi-Drug-Resistant <i>Enterobacteriales</i> , Including Carbapenem-Resistant Strains. <i>ACS Infectious Diseases</i> , 2020, 6, 1389-1397.	3.8	25
13	<i>In vitro</i> growth of multidrug-resistant <i>Neisseria gonorrhoeae</i> isolates is inhibited by ETX0914, a novel spiropyrimidinetrione. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 328-330.	2.5	17
14	Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	15
15	Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the \hat{I}^2 -Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282. <i>ACS Infectious Diseases</i> , 2020, 6, 1378-1388.	3.8	13
16	Challenges and opportunities in the discovery, development, and commercialization of pathogen-targeted antibiotics. <i>Drug Discovery Today</i> , 2021, 26, 2084-2089.	6.4	10
17	Determination of MIC Quality Control Ranges for the Novel Gyrase Inhibitor Zoliflodacin. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	7
18	Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0129221.	3.2	5

#	ARTICLE	IF	CITATIONS
19	Human Pharmacokinetics and Dose Projection of ETX2514/Sulbactam Combination for Use in the Treatment of Infections Caused by <i>Acinetobacter baumannii</i> . <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	1